dealing with a randomized prospective study of early discharge following autologous peripheral SCT (PBSCT).
We report our experience of a homogeneous cohort of patients with multiple myeloma who received an autologous PBSCT with early discharge after stem cell re-infusion and systematic readmission on day þ 5.
From April 2005 to July 2011, 94 patients received high-dose Melphalan 200 mg/m 2 (HDM) PBSCT. Conditioning was administered at day 1 and PBSCT was given on day 0. Seventy-nine patients were discharged on day þ 1 for a systematic readmission on day þ 5 or earlier in the event of complications. Fifteen patients among 94 (11%) were not discharged early as they presented exclusion criteria: social, psychological reasons, previous severe infectious complications or 490 min of travel by car to the hospital.
Patients and their relatives were broadly instructed to recognize adverse events. The ward phone number and a date for their hospitalisation 5 days later were given to them.
During the outpatient period, no antibiotic prophylaxis was used. All patients received G-CSF. Blood counts were not assessed during this period. Antiemetics were systematically prescribed. In case of any side effect as mucositis, fever or digestive pain, they could call the haematological ward.
During the following neutropenic inpatient period, they were hospitalised in a room without positive-pressure but with protective isolation. There was no antinfective prophylaxis. Empirical treatment of febrile neutropenia applied ECIL rules: anti-gram negative bacteria antibiotics were started, after blood cultures and clinical evaluation, when the temperature was 38.3 1C on two consecutive occasions or above 38.5 1C once. 2 Patients received if necessary irradiated and filtered blood products to keep Hb above 80 g/L and the platelet count above 20 G/L.
Of the 79 procedures eligible for our mixed inpatientoutpatient management regimen, none required early readmission for complications. Full engraftment was achieved in all cases. Median age was 58 years (min ¼ 31; max ¼ 71). Sex ratio was 33/46. All patients presented with multiple myeloma (IgGK ¼ 30 patients; IgGL ¼ 18 patients; free light chain ¼ 17; IgAK ¼ 2; IgAL ¼ 5). Patients were treated in first line by bortezomib (n ¼ 61) or with anthracyclines (n ¼ 31). After first-line treatment, 5/79 patients were in CR, 63 in PR and other patients were in PR after a second-line treatment. Median time to obtain neutrophil count 40.5 Â 10 9 /L was 11 days (Table 1) . During the home period, digestive toxicities occurred in 28 patients: 3 patients had oral mucositis (1 patient with grade 4), 10 patients had associated diarrhoea, 7 patients had vomiting and 6 patients had anorexia. Two patients presented fever without septic shock at home just before coming back in the hospital.
During hospitalisation, 69 patients experienced febrile neutropenia. Median duration of fever was 2 days (min ¼ 0; max ¼ 10). Twenty-three patients presented clinical infection, 17 patients had documented infection by positive blood tests. Median duration of antibiotic treatment was 5 days (range 0-22). Median time to discharge (from day 0) was 12 days (range 8-22). There was no mortality by at day 100.
Recently, there has been considerable concern regarding the appropriate use of health care resources and attempts have been made to reduce costs associated with PBSCT. As a result, strategies that reduce hospitalisation and maintain safety of care are of considerable importance.
Several studies have shown that high-dose chemotherapy and supportive care are feasible and safe in the outpatient setting. Three models have been described until now.
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Anastasia's model that we apply in our unit is less ambitious, but easier and safe: of the 123 procedures eligible for this model, 5% required early readmission because of fever, diarrhoea, severe oral mucositis, nausea and vomiting or allergic exanthema. 7 In our experience, none of the 79 discharged patients was readmitted before the scheduled readmission on day 5. There was no mortality during this procedure. There is also evidence that patients prefer to stay at home and that their quality of life is thereby enhanced. The lack of reimbursement owing to shortening the duration of the hospitalisation was partially compensated by treating additional patients during the 5 days. Our experience of early discharge after HDM and PBSCT with readmission on day þ 5 is safe and feasible with acceptable frequencies of haematological and extra-haematological toxicities. This model doesn't require the availability of dedicated specialized staff in the patient's home. The regimen allows reduced hospital stay and hence cost savings. This method generated economy of 395 hospitalisation days, which were used for treating additional patients.
